Low-dose valganciclovir for cytomegalovirus prophylaxis in heart transplant recipients

K. G. Julian, E. Shattahi, J. E. Burg, J. P. Boehmer

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We retrospectively assessed our center's experience with a protocol of low-dose (450 mg once daily) valganciclovir administered for 3-6 months (median 5 months) in a cohort of of 55 cytomegalovirus (CMV) donor-positive (D+) and/or recipient-positive (R+) heart transplant recipients. Although no CMV disease occurred in patients while receiving low-dose valganciclovir, during the 12-month post-transplantation observation period of this study, 4 (22.2%) of the 18 D+/R- patients and 1 (2.7%) of the 37 R+ patients developed symptomatic CMV viremia. Leukopenia was frequent, including neutropenia [absolute neutrophil count (ANC), <1,000 cells/μL] that occurred in 21.8% and severe neutropenia (ANC <500 cells/μL) in 7.3%. Among CMV R+ heart transplant recipients, low-dose valganciclovir appeared to be an effective, less expensive strategy for CMV prophylaxis; however, caution may be necessary among D+/R- recipients.

Original languageEnglish (US)
Pages (from-to)3414-3417
Number of pages4
JournalTransplantation proceedings
Volume45
Issue number9
DOIs
StatePublished - Nov 1 2013

Fingerprint

Cytomegalovirus
Neutropenia
Neutrophils
Viremia
Leukopenia
Transplantation
Observation
valganciclovir
Transplant Recipients
Tissue Donors

All Science Journal Classification (ASJC) codes

  • Surgery
  • Transplantation

Cite this

@article{f06f0aef0c954377a2d8314bd63cd9e8,
title = "Low-dose valganciclovir for cytomegalovirus prophylaxis in heart transplant recipients",
abstract = "We retrospectively assessed our center's experience with a protocol of low-dose (450 mg once daily) valganciclovir administered for 3-6 months (median 5 months) in a cohort of of 55 cytomegalovirus (CMV) donor-positive (D+) and/or recipient-positive (R+) heart transplant recipients. Although no CMV disease occurred in patients while receiving low-dose valganciclovir, during the 12-month post-transplantation observation period of this study, 4 (22.2{\%}) of the 18 D+/R- patients and 1 (2.7{\%}) of the 37 R+ patients developed symptomatic CMV viremia. Leukopenia was frequent, including neutropenia [absolute neutrophil count (ANC), <1,000 cells/μL] that occurred in 21.8{\%} and severe neutropenia (ANC <500 cells/μL) in 7.3{\%}. Among CMV R+ heart transplant recipients, low-dose valganciclovir appeared to be an effective, less expensive strategy for CMV prophylaxis; however, caution may be necessary among D+/R- recipients.",
author = "Julian, {K. G.} and E. Shattahi and Burg, {J. E.} and Boehmer, {J. P.}",
year = "2013",
month = "11",
day = "1",
doi = "10.1016/j.transproceed.2013.08.023",
language = "English (US)",
volume = "45",
pages = "3414--3417",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "9",

}

Low-dose valganciclovir for cytomegalovirus prophylaxis in heart transplant recipients. / Julian, K. G.; Shattahi, E.; Burg, J. E.; Boehmer, J. P.

In: Transplantation proceedings, Vol. 45, No. 9, 01.11.2013, p. 3414-3417.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Low-dose valganciclovir for cytomegalovirus prophylaxis in heart transplant recipients

AU - Julian, K. G.

AU - Shattahi, E.

AU - Burg, J. E.

AU - Boehmer, J. P.

PY - 2013/11/1

Y1 - 2013/11/1

N2 - We retrospectively assessed our center's experience with a protocol of low-dose (450 mg once daily) valganciclovir administered for 3-6 months (median 5 months) in a cohort of of 55 cytomegalovirus (CMV) donor-positive (D+) and/or recipient-positive (R+) heart transplant recipients. Although no CMV disease occurred in patients while receiving low-dose valganciclovir, during the 12-month post-transplantation observation period of this study, 4 (22.2%) of the 18 D+/R- patients and 1 (2.7%) of the 37 R+ patients developed symptomatic CMV viremia. Leukopenia was frequent, including neutropenia [absolute neutrophil count (ANC), <1,000 cells/μL] that occurred in 21.8% and severe neutropenia (ANC <500 cells/μL) in 7.3%. Among CMV R+ heart transplant recipients, low-dose valganciclovir appeared to be an effective, less expensive strategy for CMV prophylaxis; however, caution may be necessary among D+/R- recipients.

AB - We retrospectively assessed our center's experience with a protocol of low-dose (450 mg once daily) valganciclovir administered for 3-6 months (median 5 months) in a cohort of of 55 cytomegalovirus (CMV) donor-positive (D+) and/or recipient-positive (R+) heart transplant recipients. Although no CMV disease occurred in patients while receiving low-dose valganciclovir, during the 12-month post-transplantation observation period of this study, 4 (22.2%) of the 18 D+/R- patients and 1 (2.7%) of the 37 R+ patients developed symptomatic CMV viremia. Leukopenia was frequent, including neutropenia [absolute neutrophil count (ANC), <1,000 cells/μL] that occurred in 21.8% and severe neutropenia (ANC <500 cells/μL) in 7.3%. Among CMV R+ heart transplant recipients, low-dose valganciclovir appeared to be an effective, less expensive strategy for CMV prophylaxis; however, caution may be necessary among D+/R- recipients.

UR - http://www.scopus.com/inward/record.url?scp=84887056297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887056297&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2013.08.023

DO - 10.1016/j.transproceed.2013.08.023

M3 - Article

C2 - 24182826

AN - SCOPUS:84887056297

VL - 45

SP - 3414

EP - 3417

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 9

ER -